← Leaderboards
Anuradha Mahadevan
Organix, Inc.
$5,455,160
Attributed
$6,059,770
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $863.3K · FY2005–18$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$6,059,770 · 9
By mechanism
R44$1,731,475 · 1
R01$1,388,826 · 1
R43$1,227,531 · 4
P01$1,209,220 · 2
R03$502,718 · 1
Top collaborators
- Raj Razdan5 shared
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogPharmaceutical PreparationsCannabinoidsLeadBaseReceptor, Cannabinoid, Cb1Binding (Molecular Function)In VivoDesignReceptor, Cannabinoid, Cb2PeripheralLigandsCannabinoid ReceptorPainSeriesPropertyReceptorAnandamideInflammationMetabolicProgramsTissuesAgonistInhibitor/Antagonist
Grant awards (20)
Targeting Breast Cancer Metastasis with Id1$743,502
R44 · FY2018 · CA · contact PI
Targeting Breast Cancer Metastasis with Id1$809,827
R44 · FY2017 · CA · contact PI
Targeting Breast Cancer Metastasis with Id1$178,146
R44 · FY2016 · CA · contact PI
Targeting breast cancer metastasis with inhibitors of Id-1$289,823
R43 · FY2013 · CA · contact PI
Cannabinoid Receptor Agonists for Treatment of Chronic Pain$279,256
R43 · FY2013 · DA · contact PI
Project 2$258,754
P01 · FY2013 · DA
Project 2$221,814
P01 · FY2012 · DA
Synthesis of delta9-Tetrahydrocannabinol Related Compounds$337,617
R01 · FY2011 · DA · contact PI
Project 2$241,777
P01 · FY2011 · DA
Synthesis of delta9-Tetrahydrocannabinol Related Compounds$348,059
R01 · FY2010 · DA · contact PI
Project 2$239,574
P01 · FY2010 · DA
Development of CB2 Agonists for Treatment of Pain$238,343
R03 · FY2010 · DA · contact PI
Synthesis of delta9-Tetrahydrocannabinol Related Compounds$351,575
R01 · FY2009 · DA · contact PI
Development of CB2 Agonists for Treatment of Pain$264,375
R03 · FY2009 · DA · contact PI
Project 2$247,301
P01 · FY2009 · DA
Synthesis of delta9-Tetrahydrocannabinol Related Compounds$351,575
R01 · FY2008 · DA · contact PI
CB2 Agonists for Treatment of Neuropathic Pain.$130,505
R43 · FY2008 · NS · contact PI
Novel THC/Anandamide Hybrids as Appetite Suppressants$23,736
R43 · FY2008 · DK · contact PI
Novel THC/Anandamide Hybrids as Appetite Suppressants$244,419
R43 · FY2006 · DK · contact PI
Novel THC/Anandamide Hybrids as Appetite Suppressants$259,792
R43 · FY2005 · DK